3.1 Acetaminophen Overdose: Pathophysiology, Rumack-Matthew Nomogram, and NAC Protocols

Acetaminophen (N-acetyl-p-aminophenol, paracetamol, APAP) is the most widely utilized analgesic and antipyretic in the world. It is also the leading cause of acute liver failure and the most common pharmaceutical agent involved in intentional self-poisoning reported to poison centers. Mastery of APAP kinetics, bioactivation pathways, diagnostic timing windows, antidote administration protocols, and liver transplant referral criteria is central to clinical toxicology practice.

---

Hepatic Biotransformation and NAPQI Bioactivation

Under therapeutic dosing conditions (maximum 4,000 mg daily in adults), acetaminophen is rapidly absorbed from the gastrointestinal tract, achieving peak serum concentrations within 60 to 120 minutes. It undergoes extensive hepatic biotransformation through three primary metabolic pathways:

1. Glucuronidation (50% to 60%): UDP-glucuronosyltransferases (primarily UGT1A6, UGT1A9, and UGT2B15) conjugate APAP into non-toxic acetaminophen-glucuronide, excreted renally.
2. Sulfation (30% to 44%): Sulfotransferases (primarily SULT1A1) conjugate APAP into non-toxic acetaminophen-sulfate, excreted renally. This high-affinity, low-capacity pathway saturates at relatively low toxic doses.
3. Renal Excretion Unchanged (less than 5%): A minor fraction is filtered directly through the glomerulus.
4. Cytochrome P450 Oxidation (5% to 10%): Biotransformation mediated primarily by CYP2E1 (with minor contributions from CYP1A2, CYP2A6, and CYP3A4) oxidizes APAP into the highly reactive, electrophilic intermediate N-acetyl-p-benzoquinone imine (NAPQI).

The Cascade of Centrilobular Necrosis

Under normal conditions, intracellular glutathione (GSH) spontaneously or enzymatically binds NAPQI via sulfhydryl groups, forming harmless, water-soluble mercapturic acid and cysteine conjugates excreted in urine.

In acute overdose, the primary phase II glucuronidation and sulfation pathways saturate rapidly. An increased fraction of APAP is shunted through CYP2E1, causing a massive surge in NAPQI production. When endogenous hepatic glutathione stores are depleted by 70% to 80% (falling below approximately 20% to 30% of normal baseline), free NAPQI can no longer be detoxified. Unconjugated NAPQI covalently binds to nucleophilic sulfhydryl groups on hepatocellular proteins—specifically targeting mitochondrial proteins such as ATP synthase alpha-subunit and complex I/II enzymes. This binding induces:

• Severe mitochondrial oxidative stress and accumulation of reactive oxygen species (ROS)
• Opening of the mitochondrial permeability transition (MPT) pore
• Complete collapse of mitochondrial membrane potential and loss of ATP synthesis
• Cell swelling, nuclear DNA fragmentation, and acute centrilobular Zone 3 necrosis (the perivenular region where CYP2E1 expression is highest and baseline oxygen tension is lowest).

High-Risk Susceptibility States

Certain patient populations experience profound hepatotoxicity at lower ingested thresholds due to baseline alterations in biotransformation:

• Chronic Ethanol Abuse: Ethanol induces CYP2E1 enzyme activity during periods of withdrawal or sobriety, while concomitant malnutrition frequently depletes baseline hepatic glutathione.
• Malnutrition, Fasting, and Anorexia: Prolonged nutritional deprivation depletes intracellular cysteine and glutathione reserves, lowering the threshold for free NAPQI accumulation.
• Enzyme-Inducing Medications: Concomitant use of rifampin, phenytoin, phenobarbital, carbamazepine, or St. John's wort induces CYP isoenzymes, accelerating NAPQI generation.
• Isoniazid (INH): Co-ingestion or chronic therapy dramatically induces CYP2E1 activity.

---

Clinical Stages of Acetaminophen Hepatotoxicity

The clinical presentation of acetaminophen poisoning evolves over four distinct chronological stages. Recognizing these stages prevents the critical error of falsely reassuring an asymptomatic patient during the early latent window.

---

The Rumack-Matthew Nomogram: Diagnostic Timing and Limitations

The Rumack-Matthew nomogram is an internationally recognized logarithmic decision tool correlating serum acetaminophen concentration and time post-ingestion with the likelihood of severe hepatotoxicity (defined as peak AST greater than 1,000 IU/L).

Operational Rules and the 4-Hour Post-Ingestion Level

1. Acute Single Ingestions Only: The nomogram is valid strictly for single, acute, known-time ingestions presenting within 24 hours of ingestion. It cannot be applied to repeated supratherapeutic ingestions, chronic ingestions, staggered doses, or exposures with an unknown time of ingestion.
2. The 4-Hour Rule: The nomogram begins at exactly 4 hours post-ingestion. Serum levels drawn prior to 4 hours cannot be interpreted or plotted because active gastrointestinal absorption and tissue distribution are incomplete. If a level is drawn at 2 hours post-ingestion, a repeat specimen must be obtained at or after 4 hours.
3. Treatment Lines:
   • The original nomogram established the "probable toxicity line" starting at 200 mcg/mL (1320 umol/L) at 4 hours.
   • In the United States, regulatory and clinical guidelines mandate the use of the more conservative "treatment line" (often termed the 150-line), starting at 150 mcg/mL (1000 umol/L) at 4 hours and ending at 4.7 mcg/mL at 24 hours. This incorporates a 25% safety margin to account for potential inaccuracies in history and assay variability. Any patient whose plotted level falls at or above this treatment line must receive immediate N-acetylcysteine therapy.

Special Ingestion Kinetics

• Extended-Release (ER) Formulations: Acetaminophen extended-release formulations contain 50% immediate-release and 50% slow-release matrices. Delayed or erratic absorption can lead to a second, higher concentration peak. Poison center protocol dictates drawing an initial level at 4 hours post-ingestion, followed by a mandatory second level drawn 4 to 6 hours later. If either concentration plots at or above the nomogram line, or if the second level is rising, a complete course of NAC must be initiated.
• Co-ingestants Altering Motility: Concomitant ingestion of anticholinergic medications (e.g., diphenhydramine) or opioids (e.g., oxycodone, codeine) significantly impairs gastric motility and delays intestinal transit. A standard 4-hour level may underestimate toxicity; serial levels drawn 4 hours apart are mandatory if the initial concentration is below the line but ongoing absorption is suspected.

N-Acetylcysteine (NAC) Pharmacodynamics and Dosing Regimens

N-acetylcysteine is a highly effective, specific antidote that prevents hepatotoxicity when initiated within 8 hours of acute overdose, reducing the incidence of severe liver injury to less than 2% to 5%. However, NAC is life-saving and indicated at any time point post-ingestion if active liver injury or detectable drug persists.

Pharmacodynamic Mechanisms

1. Glutathione Precursor: NAC is hydrolyzed intracellularly to L-cysteine, the rate-limiting amino acid precursor required for hepatic glutathione synthesis.
2. Direct Detoxification: NAC can directly bind and reduce NAPQI through its free sulfhydryl (-SH) group.
3. Sulfate Conjugation Substrate: NAC provides inorganic sulfate to restore Phase II sulfation pathways.
4. Antioxidant and Microvascular Support in Fulminant Failure: In established Stage III hepatic failure, even after all acetaminophen has cleared, NAC acts as a potent free-radical scavenger, improves hepatic microcirculatory blood flow, enhances systemic oxygen delivery, reduces cerebral edema, and provides inotropic cardiovascular support.

Intravenous vs. Oral Protocols

Both intravenous and oral formulations demonstrate equivalent clinical efficacy if completed properly, but their operational profiles differ substantially.

Managing Non-Immunologic Anaphylactoid Reactions to IV NAC

Anaphylactoid reactions to IV NAC occur in up to 10% to 20% of patients, typically during the high-concentration loading dose infusion. These reactions are non-IgE-mediated histamine release phenomena, not true type-I allergies.

• Mild symptoms (isolated flushing or mild erythema): Reassure the patient, continue the infusion under close observation.
• Moderate symptoms (urticaria, pruritus, mild wheezing): Temporarily pause the infusion, administer IV diphenhydramine (25 to 50 mg), and restart the infusion at a slower rate once symptoms resolve.
• Severe reactions (systemic hypotension, severe bronchospasm, angioedema): Discontinue the infusion immediately, administer intramuscular epinephrine (0.3 mg IM 1:1,000), provide aggressive fluid resuscitation, and transition to the oral NAC protocol once hemodynamically stable.

---

Contemporary NAC Discontinuation Criteria

Historically, the 21-hour IV protocol was stopped rigidly at the conclusion of the 21 hours. Modern evidence-based toxicology dictates that treatment must be tailored to clinical and biochemical endpoints, not a fixed timer. Prior to discontinuing the third IV bag (typically at hour 20 to 22), serum transaminases, acetaminophen concentration, and INR must be reassessed.

Discontinuation Criteria (All must be fulfilled before stopping NAC):

1. Serum acetaminophen concentration is undetectable (less than 10 mcg/mL).
2. Serum transaminases (AST and ALT) are either entirely normal OR, if elevated, are clearly declining from their peak (many protocols look for a fall of about 25% to 50%).
3. INR is below 2.0.
4. The patient is clinically well with no abdominal tenderness or encephalopathy.

Action if Criteria Are Not Met: Do NOT discontinue therapy. Continue intravenous NAC at the third-bag maintenance rate (100 mg/kg infused over 16 hours, equivalent to 6.25 mg/kg/hour) and recheck laboratory parameters every 12 hours until all stopping criteria are met.

---

Massive Overdose and Mitochondrial Shock

A distinct clinical entity known as massive acetaminophen overdose occurs when an acute ingestion exceeds 30 to 50 grams or produces initial 4-hour serum levels greater than 300 to 500 mcg/mL (often exceeding 800 to 1,000 mcg/mL).

Clinical Presentation

Unlike classic Stage I presentations, patients with massive overdoses can develop early mitochondrial toxicity within 4 to 12 hours post-ingestion, characterized by:

• Early deep coma and central nervous system depression independent of co-ingestants
• Severe, refractory high-anion-gap lactic acidosis (lactate often 8 to 15 mmol/L)
• Hemodynamic instability and shock
• Normal or minimally elevated hepatic transaminases at presentation (mitochondrial respiration is poisoned directly before widespread hepatocellular lysis occurs).

Management Adaptation

In massive overdose, standard NAC dosing (designed around ingestions near the treatment line) can be overwhelmed by the sheer mass of circulating APAP and NAPQI. Common adaptations include:

• Increasing the NAC Dose: Doubling the maintenance infusion rate (12.5 mg/kg/hour) or administering an additional 150 mg/kg load. The 2023 US and Canada consensus statement notes that many clinicians increase the dose above the 300 mcg/mL line, but the evidence does not support one specific regimen.
• Hemodialysis: Intermittent hemodialysis removes both parent acetaminophen and toxic organic acids, while clearing lactate. EXTRIP recommends it when the APAP concentration exceeds 1,000 mg/L (1,000 mcg/mL) without NAC, or when altered mental status, metabolic acidosis, and an elevated lactate accompany a concentration above 700 mg/L without NAC, and suggests it above 900 mg/L with those features even when NAC has been given. The 2023 US and Canada consensus statement recommends hemodialysis at 900 mcg/mL or more with acidosis or altered consciousness. NAC is removed by dialysis, so continue it at an increased rate during the run.

---

King's College Criteria for Emergent Liver Transplantation

When acute acetaminophen-induced liver injury progresses to fulminant hepatic failure, medical therapy alone carries a mortality rate exceeding 80%. The King's College Criteria are the gold standard for triggering immediate listing for orthotopic liver transplantation in acetaminophen-induced acute liver failure.

An immediate transplant evaluation is indicated if the patient fulfills either of the following criteria:

1. Arterial Blood pH less than 7.30 measured after adequate fluid resuscitation (regardless of the clinical grade of encephalopathy).

OR

1. All three of the following parameters within a concurrent 24-hour period:
   • Development of Grade III or IV hepatic encephalopathy (confusion, stupor, or coma)
   • Serum creatinine greater than 3.4 mg/dL (greater than 300 umol/L) indicating hepatorenal syndrome
   • Prothrombin time greater than 100 seconds (or INR greater than 6.5)

Prognostic Adjunct: Arterial lactate greater than 3.5 mmol/L after initial fluid resuscitation, or greater than 3.0 mmol/L after full fluid resuscitation (about 12 hours after admission), is an early, validated independent predictor of mortality in acetaminophen-induced fulminant hepatic failure.